Cargando…
Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity
PURPOSE: To describe the efficacy of intravitreal bevacizumab for the treatment of type 1 retinopathy of prematurity (ROP) in zone I. METHODS: Preterm infants with type 1 ROP in zone I (zone I ROP, any stage with plus disease or zone I ROP, stage 3 without plus disease) were enrolled in this prospec...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782452/ https://www.ncbi.nlm.nih.gov/pubmed/29403586 http://dx.doi.org/10.4103/jovr.jovr_198_16 |
_version_ | 1783295196774006784 |
---|---|
author | Karkhaneh, Reza Torabi, Hamidreza Khodabande, Alireza Roohipoor, Ramak Riazi-Esfahani, Mohammad |
author_facet | Karkhaneh, Reza Torabi, Hamidreza Khodabande, Alireza Roohipoor, Ramak Riazi-Esfahani, Mohammad |
author_sort | Karkhaneh, Reza |
collection | PubMed |
description | PURPOSE: To describe the efficacy of intravitreal bevacizumab for the treatment of type 1 retinopathy of prematurity (ROP) in zone I. METHODS: Preterm infants with type 1 ROP in zone I (zone I ROP, any stage with plus disease or zone I ROP, stage 3 without plus disease) were enrolled in this prospective study. Intravitreal bevacizumab (0.625 mg/0.025 ml) was injected under topical anesthesia. Patients were followed weekly for 4 weeks and then biweekly till 90 weeks gestational age. RESULTS: Seventy eyes of 35 patients with type 1 ROP in zone I were enrolled. At a gestational age of 90 weeks, ROP regressed with complete or near-complete peripheral retinal vascularization, in 82.9% of eyes after a single injection and in 92.9% of eyes after up to two injections. In five eyes (7.1%), ROP progressed to stage 4B or 5, so surgical management was required. There were no major complications such as endophthalmitis, cataract, or vitreous hemorrhage after injection. CONCLUSION: Intravitreal bevacizumab injection is an effective method for the management of patients with Zone I ROP requiring treatment; however, some cases may progress to more advanced stages and require surgical management. Close monitoring for recurrence or progression is necessary. Eyes with persistent zone I ROP may progress to advanced stages when treated with intravitreal bevacizumab injection and re-treatment may be needed. |
format | Online Article Text |
id | pubmed-5782452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-57824522018-02-05 Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity Karkhaneh, Reza Torabi, Hamidreza Khodabande, Alireza Roohipoor, Ramak Riazi-Esfahani, Mohammad J Ophthalmic Vis Res Original Article PURPOSE: To describe the efficacy of intravitreal bevacizumab for the treatment of type 1 retinopathy of prematurity (ROP) in zone I. METHODS: Preterm infants with type 1 ROP in zone I (zone I ROP, any stage with plus disease or zone I ROP, stage 3 without plus disease) were enrolled in this prospective study. Intravitreal bevacizumab (0.625 mg/0.025 ml) was injected under topical anesthesia. Patients were followed weekly for 4 weeks and then biweekly till 90 weeks gestational age. RESULTS: Seventy eyes of 35 patients with type 1 ROP in zone I were enrolled. At a gestational age of 90 weeks, ROP regressed with complete or near-complete peripheral retinal vascularization, in 82.9% of eyes after a single injection and in 92.9% of eyes after up to two injections. In five eyes (7.1%), ROP progressed to stage 4B or 5, so surgical management was required. There were no major complications such as endophthalmitis, cataract, or vitreous hemorrhage after injection. CONCLUSION: Intravitreal bevacizumab injection is an effective method for the management of patients with Zone I ROP requiring treatment; however, some cases may progress to more advanced stages and require surgical management. Close monitoring for recurrence or progression is necessary. Eyes with persistent zone I ROP may progress to advanced stages when treated with intravitreal bevacizumab injection and re-treatment may be needed. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC5782452/ /pubmed/29403586 http://dx.doi.org/10.4103/jovr.jovr_198_16 Text en Copyright: © 2018 Journal of Ophthalmic and Vision Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Karkhaneh, Reza Torabi, Hamidreza Khodabande, Alireza Roohipoor, Ramak Riazi-Esfahani, Mohammad Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity |
title | Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity |
title_full | Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity |
title_fullStr | Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity |
title_full_unstemmed | Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity |
title_short | Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity |
title_sort | efficacy of intravitreal bevacizumab for the treatment of zone i type 1 retinopathy of prematurity |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782452/ https://www.ncbi.nlm.nih.gov/pubmed/29403586 http://dx.doi.org/10.4103/jovr.jovr_198_16 |
work_keys_str_mv | AT karkhanehreza efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity AT torabihamidreza efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity AT khodabandealireza efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity AT roohipoorramak efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity AT riaziesfahanimohammad efficacyofintravitrealbevacizumabforthetreatmentofzoneitype1retinopathyofprematurity |